



PATENT CASE: DX0935K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of: Oppmann *et al.* :
For: Mammalian Cytokines; Related Reagents :
and Methods :
Serial No.: 09/521,335 :
Filing Date: March 9, 2000 :
-----X

Examiner: To be assigned
Group Art Unit: 1643

RECEIVED
SEP 12 2000
H.S.
Plunkett
10/28/00
TECH CENTER 1600/2900

September 1, 2000
Schering-Plough Corporation
Kenilworth, New Jersey 07033

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir or Madam:

Applicants respectfully request that the following documents, as listed below and on the accompanying form PTO-1449, be considered and made of record in the above-identified application. Enclosed is a copy of the International Search Report received in connection with Applicants' corresponding PCT application. Copies of documents that were listed in the International Search Report are attached unless previously cited in the priority application Serial No. 09/267,901, filed March 11, 1999, Docket No. DX0935. No further copies will be provided absent specific request.

U.S. PATENT DOCUMENTS

5,457,038

5,741,772

FOREIGN PATENT DOCUMENTS

WO 98/33922

WO 99/00415

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on this 1st day of September 2000.

September 1, 2000 _____
Date Signature Sandy S. Zaradic, Ph.D.
Reg. No.45,997



WO 98/11225

WO 98/31811

WO 98/49307

EP 0 759 466

WO 95/11303

WO 99/20755

WO 99/28462

WO 99/35264

WO 99/40195

OTHER DOCUMENTS

DeChiara *et al.*, "Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth", *Cell*, 83:313-322 (1995).

Elson *et al.*, "Definition: 'Homo sapiens cytokine-like factor-1 precursor (CLF-1) mRNA, complete cds'", *GenBank*, Accession Number AF059293 (1998).

Elson *et al.*, "Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family", *J Immunol*, 161:1371-1379 (1998).

Gately *et al.*, "The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses", *Annu Rev Immunol*, 16:495-521 (1998).

Gough *et al.*, "Definition: 'Murine mRNA for leukaemia inhibitory factor (LIF)'", *GenBank*, Accession Number X06381 (1995).

Habecker *et al.*, "A sweat gland-derived differentiation activity acts through known cytokine signaling pathways", *J Biol Chem*, 272:30421-30428 (1997).

McDonald, "Definition: 'Human CNTF gene for ciliary neurotrophic factor'", *GenBank*, Accession Number X60542 (1991).

Pennica *et al.*, "Definition: 'Mus musculus cardiotrophin-1 mRNA, complete cds'", *GenBank*, Accession Number U18366 (1995).

Pennica *et al.*, "Definition: 'Human cardiotrophin-1 (CTF1) mRNA, complete cds'", *GenBank*, Accession Number U43030 (1996).

Saotome *et al.*, "Definition: 'Mus musculus zinc finger protein (Pzf) mRNA, partial cds, and ciliary neurotrophic factor (Cntf) mRNA, complete cds'", *GenBank*, Accession Number U05342 (1995).

Shelton, "Are there more members of the CNTF-GPA family?", *Persp Devel Neurobiol*, 4:101-107 (1996).

Stahl *et al.*, "Definition: 'Human leukemia inhibitory factor (LIF) gene, complete cds'", *GenBank*, Accession Number M63420, J05436 (1994).

Trinchieri, "Proinflammatory and immunoregulatory functions of interleukin-12", *Intern Rev Immunol*, 16:365-396 (1998).

Ware *et al.*, "Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death", *Development*, 121:1283-1299 (1995).

Database DGENE, Last updated 13-JUN-1999, Result from sequence search using SEQ ID NO: 2, as the query and citing Accession Numbers: 99P-W94466, 98P-W56141, 98P-W29715, 98P-W56142, 98P-W29716, 97P-W29237, 96P-R88204, 95P-R83965; Derwent Information Ltd., London.

Database DGENE, Last updated 13-JUN-1999, Result from sequence search using SEQ ID NO: 12, as the query and citing Accession Numbers: 98P-W59805, 98P-W55012, 98P-W55011, 98P-W59804, 98P-W55014, 98P-W55015, 98P-W55016, 92P-R26334, 97P-W17859, 96P-R94576, 92P-R24273, 92P-R22228, 91P-R10795; Derwent Information Ltd., London.

Fischer *et al.*, "A bioactive designer cytokine for human hematopoietic progenitor cell expansion", *Nat Biotechnol*, 15:142-145 (1997).

Peters *et al.*, "In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6", *J Immunol*, 161:3575-3581 (1998).


Rakemann *et al.*, "The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription *in vivo* and *in vitro*", *J Biol Chem*, 274:1257-1266 (1999).

Shi *et al.*, "Computational EST database analysis identifies a novel member of the neuropoietic cytokine family", *Biochem Biophys Res Commun*, 262:132-138 (1999).

Senaldi *et al.*, "Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family", *Proc Natl Acad Sci USA*, 96:11458-11463 (1999).

Applicant's submission of this Information Disclosure Statement is not an admission that any reference cited herein qualifies as prior art.

Respectfully submitted,


Sandy S. Zaradis, Ph.D.
Attorney for Applicants
Registration No. 45,997

Schering-Plough Corporation
Patent Department K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
Telephone No. (908) 298-7221

SEP 06 2000



FF TC-1600

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/521,335
Filing Date	March 9, 2000
First Named Inventor	Oppmann et al.
Group Art Unit	1643
Examiner Name	to be assigned
Attorney Docket Number	DX0935K

Total Number of Pages in This Submission 6

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) PTO Form 1449 - 2 pages References - 14 International Search Report - 9 pages
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Sandy S. Zaradic
Signature	<i>Sandy Zaradic</i>
Date	September 1, 2000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: Sept. 1, 2000	
Typed or printed name	Sandy S. Zaradic
Signature	<i>Sandy Zaradic</i>
Date	September 1, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY